Xenograft Model Antitumor Assays

JUL 14, 2026 · JOURNAL ARTICLE

Efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy versus photothermal therapy alone for breast cancer xenograft tumors: a meta-analysis.

International Journal of Hyperthermia

Meta-analysis of preclinical xenograft models demonstrates significant tumor suppression, but limited safety and translational data prevent clinical extrapolation.

JUN 22, 2026

KIF18A inhibitor prevents chromosomally unstable osteosarcoma growth by activating spindle assembly checkpoint.

Cancer Biology & Therapy

Preclinical cell-line and xenograft data showing anti-tumor activity of a KIF18A inhibitor in osteosarcoma models without human trial evidence.

JUN 10, 2026 · JOURNAL ARTICLE

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.

Mabs

Preclinical proof-of-concept study in xenograft models demonstrating enhanced anti-tumor activity with a novel CD2-targeted bispecific; no clinical efficacy or safety data provided.

JUN 7, 2026 · JOURNAL ARTICLE

Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.

Gut Microbes

Mechanistic preclinical study with xenograft and clinical sample data identifying gut microbial metabolism as a contributor to flutamide resistance, with potential for personalized therapy but lacking clinical trial evidence of efficacy.

MAY 26, 2026 · JOURNAL ARTICLE

Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis.

Cancer Biology & Therapy

In vitro and database study identifying lncRNA AC008406.3 as a cuproptosis regulator affecting docetaxel sensitivity in breast cancer cells, lacking clinical validation or human efficacy data.